Legend Biotech Corp ADR (NASDAQ: LEGN) kicked off on Thursday, down -1.97% from the previous trading day, before settling in for the closing price of $33.46. Over the past 52 weeks, LEGN has traded in a range of $29.27-$60.87.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 71.28% over the past five years. While this was happening, its average annual earnings per share was recorded 18.06%. With a float of $181.14 million, this company’s outstanding shares have now reached $183.65 million.
Let’s look at the performance matrix of the company that is accounted for 2609 employees. In terms of profitability, gross margin is 61.69%, operating margin of -37.28%, and the pretax margin is -25.21%.
Legend Biotech Corp ADR (LEGN) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Legend Biotech Corp ADR is 1.37%, while institutional ownership is 53.66%. The most recent insider transaction that took place on Mar 25 ’25, was worth 11,959. Before that another transaction happened on Mar 25 ’25, when Company’s Officer proposed sale 4,064 for $35.28, making the entire transaction worth $143,371.
Legend Biotech Corp ADR (LEGN) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.23 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 18.06% per share during the next fiscal year.
Legend Biotech Corp ADR (NASDAQ: LEGN) Trading Performance Indicators
Take a look at Legend Biotech Corp ADR’s (LEGN) current performance indicators. Last quarter, stock had a quick ratio of 4.54. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 9.60.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.97, a number that is poised to hit -0.21 in the next quarter and is forecasted to reach 0.52 in one year’s time.
Technical Analysis of Legend Biotech Corp ADR (LEGN)
Legend Biotech Corp ADR (NASDAQ: LEGN) saw its 5-day average volume 2.36 million, a positive change from its year-to-date volume of 1.34 million. As of the previous 9 days, the stock’s Stochastic %D was 69.58%. Additionally, its Average True Range was 1.88.
During the past 100 days, Legend Biotech Corp ADR’s (LEGN) raw stochastic average was set at 23.09%, which indicates a significant decrease from 60.45% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 58.65% in the past 14 days, which was higher than the 51.24% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $35.23, while its 200-day Moving Average is $42.92. Nevertheless, the first resistance level for the watch stands at $33.50 in the near term. At $34.21, the stock is likely to face the second major resistance level. The third major resistance level sits at $35.12. If the price goes on to break the first support level at $31.89, it is likely to go to the next support level at $30.98. The third support level lies at $30.27 if the price breaches the second support level.
Legend Biotech Corp ADR (NASDAQ: LEGN) Key Stats
The company with the Market Capitalisation of 6.02 billion has total of 183,649K Shares Outstanding. Its annual sales at the moment are 627,240 K in contrast with the sum of -177,030 K annual income. Company’s last quarter sales were recorded 186,520 K and last quarter income was 26,280 K.
